RetroSense Therapeutics, a privately-held, clinical-stage biopharmaceutical company, announced that the United States Patent and Trademark Office (USPTO) has granted U.S. patent Application No. 11/036,629, entitled “Method for Augmenting Vision in Persons Suffering from Photoreceptor Cell Degeneration.” RetroSense is the exclusive licensee of this intellectual property for augmenting vision from photoreceptor cell degeneration through a license with Massachusetts General Hospital. This patent broadly covers methods for restoring or improving vision using optogenetic approaches. The allowed claims cover the use of a broad range of opsins and rhodopsins in vision restoration.